RAD51 and neoplasm: To assess the ability of the RAD51 assay to identify HRR‐deficient tumors beyond gBRCA mutations, we scored for RAD51 in 23 FFPE tumor samples from a cohort of patients with clinical suspicion of hereditary breast cancer and without gBRCA mutations (Fig 5A).